Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 21 resultados

DE-STRESS: Detecting stress in early-forming teeth: Advancing, optimising and interpreting dental cortisol meth... THE GENERAL HOSPITAL CORPORATION participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Stress influences health and wellbeing throughout the human life course, from prenatal to final stages. However, there are multiple methodol...
2024-05-23 - 2026-12-31 | Financiado

RISK-MATTER: Psychosis risk subtypes and white matter integrity: exploring subgroup trajectories THE GENERAL HOSPITAL CORPORATION participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Psychotic disorders rank among the top 25 global causes of disability, impacting individuals, their families, and society. Much of this burd...
2024-05-08 - 2026-12-31 | Financiado

APOLLO2028: Improving mental health, wellbeing, and resilience of healthcare workers in Changing Environments THE GENERAL HOSPITAL CORPORATION participó en un HORIZON EUROPE: HORIZON-HLTH-2023-CARE-04 The overall objective of the APOLLO2028 project is to provide health and care workers, organisations, and healthcare system funders and poli...
2023-12-01 - 2027-12-31 | Financiado

ADEEPSLEEP: Focusing on deep sleep-wake brain regions in the context of Alzheimer's disease pathogenesis: a mult... THE GENERAL HOSPITAL CORPORATION participó en un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 The increased prevalence of Alzheimer’s disease (AD) in our ageing society constitutes an urgent, far-reaching public health concern. In the...
2023-05-16 - 2026-12-31 | Financiado

GBM_Cellular_States: Deciphering and targeting cellular states in glioblastoma THE GENERAL HOSPITAL CORPORATION participó en un HORIZON EUROPE: ERC-2021-COG Cellular heterogeneity is a fundamental property of glioblastoma (GBM) tumors and presents a major barrier for therapeutics. During the past...
2022-04-26 - 2027-04-30 | Financiado

IMMUNE-GENEMEMO: Identification of transcriptional memory maintenance factors through a cell selection strategy THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2020 Memory of gene expression states is essential for development and maintenance of tissues. Chromatin, a protein DNA complex, is implicated in...
2021-04-16 - 2024-05-31 | Financiado

CancerCOtreat: Optimizing treatment of cancer patients infected with COVID 19 and other preconditions using mathema... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2020 Cancer patients are of high risk to develop severe COVID-19, which has a negative impact on their clinical management. Cancer therapy and CO...
2021-04-13 - 2024-04-30 | Financiado

MAESTRIA: Machine Learning Artificial Intelligence Early Detection Stroke Atrial Fibrillation THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-SC1-BHC-2018-2020 Atrial fibrillation (AF) and stroke are major health care problems in Europe. They are most often the clinical expression of atrial cardiomy...
2021-01-21 - 2026-02-28 | Financiado

INTERVENE: International consortium for integrative genomics prediction THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-SC1-FA-DTS-2018-2020 The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing th...
2020-12-07 - 2025-12-31 | Financiado

ProCAncer-I: An AI Platform integrating imaging data and models supporting precision care through prostate cance... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-SC1-FA-DTS-2018-2020 In Europe, prostate cancer (PCa) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices, of...
2020-05-29 - 2024-09-30 | Financiado

QUALITOP: Monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherapy an Open smart d... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-SC1-DTH-2018-2020 "Cancer immunotherapy brought about significant progress in cancer treatment. It resulted in high efficacy in some cancers; e.g., up to 60%...
2019-10-28 - 2024-06-30 | Financiado

DIVE into AD: Study of tau strains to understand the phenotypic diversity of Alzheimer s disease A step toward pe... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2018 Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reac...
2019-04-30 - 2023-01-04 | Financiado

UPGRADE: Unlocking Precision Gene Therapy THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-SC1-BHC-2018-2020 Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene...
2018-12-04 - 2024-06-30 | Financiado

TANTUMorNEUVACCINE: Neutrophil subtypes distinct cellular targets for therapeutic intervention THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2016 In cancer immunotherapy and vaccine field, considerable efforts have been invested to optimize the induction of effector T cells that, by re...
2017-04-04 - 2020-09-30 | Financiado

ARTEMIS: Assessment of Reserve Translational Evaluation of Medical Images and Statistics Prediction models... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2016 Stroke and cognitive decline are among the leading contributors to disease burden and long-term disability worldwide. Despite their prevalen...
2017-03-09 - 2020-05-31 | Financiado

CONNECT: Connecting neuronal network activity with regional specificity for Alzheimer pathology a multi mod... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2015 As the world’s population is aging, the prevalence of Alzheimer’s disease (AD) is estimated to triple by 2050. Even though AD was identified...
2016-03-22 - 2019-12-31 | Financiado

INTERPLAY: Interplay between genetic determinants of glycaemia type 2 diabetes and cardiovascular disease in i... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2015 Genome-wide association studies (GWAS) for complex traits, including glycaemia, type 2 diabetes (T2D) and coronary heart disease (CHD) have...
2016-02-19 - 2021-02-06 | Financiado

REPROGRAM: Targeting epigenetic REPROGRamming of innate immune cells in Atherosclerosis Management and other ch... THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-PHC-2014-2015 Up to 70% of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immun...
2015-12-04 - 2019-12-31 | Financiado

MOvE-ECG: Moving from genome wide association to elucidating causal mechanisms of electrocardiographic traits THE GENERAL HOSPITAL CORPORATION participó en un H2020: H2020-MSCA-IF-2014 Understanding how genes and genetic variants influence heart function is of major importance, not only from a basic science viewpoint, but a...
2015-07-01 - 2017-09-30 | Financiado

TUMOR: Transatlantic TUmour MOdel Repositories THE GENERAL HOSPITAL CORPORATION participó en un FP7: The project aims at developing a European clinically oriented semantic-layered cancer digital model repository from existing EU projects tha...
Financiado